Eli Lilly's incretin manufacturing facility at Research Triangle Park in North Carolina

July 23, 2024 10:15 AM EDTUpdated July 25, 04:16 PM

The obesity drug race is being fought on the manufacturing floor as GLP-1 rivals make plans to catch leaders

Anna Brown

News Reporter

Ever since the weight loss drug craze created near-unprecedented demand, the first two companies to market have been doing everything they can to meet it …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

The obesity drug race is being fought on the manufacturing floor as GLP-1 rivals make plans to catch leaders

Anna Brown

News Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Secretive Treeline Biosciences discloses $421M financing in filing

House’s prominent China critic Jim McGovern leads opposition to Biosecure Act: ‘I would prefer to go back to the ...

RNA gene therapy startup Shape hunts for new CEO as Series C awaits

Sage shakes up senior management, slashes pipeline, sheds 33% of staff

FDA delays colorectal cancer decision for Amgen's Lumakras, a setback in race with Bristol Myers

Join the GenScript Biotech Global Forum: Unlocking Innovations in Cell and Gene Therapies

The obe­si­ty drug race is be­ing fought on the man­u­fac­tur­ing floor as GLP-1 ri­vals make plans to catch lead­ers

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

The obesity drug race is being fought on the manufacturing floor as GLP-1 rivals make plans to catch leaders